Advertisement

AN OXALIPLATIN + 5-FLUOROURACIL BOLUS + FOLINIC ACID (BFOL) REGIMEN AS FIRST-LINE TREATMENT IN METASTATIC COLORECTAL CANCER PATIENTS

Abstract

Aims and background: The purpose of the study was to evaluate the outcome of metastatic colorectal cancer patients treated, as first line, with 5-fluorouracil bolus/leucovorin + oxaliplatin, in terms of response, progression-free and overall survival.Materials and methods: A retrospective cohort of consecutive metastatic colorectal cancer patients, treated from 2003 to 2006, was identified and analyzed. All patients, without a central venous device, were treated with oxaliplatin + 5-fluorouracil and leucovorin.Results: Twenty-five metastatic colorectal cancer patients were treated. No 3-4 grade toxicity was observed. Five of 23 patients achieved a partial response: one of them resulted in a complete response after radiofrequency and another one after surgery. Fifteen of 23 patients had stable disease (one underwent radical surgery after chemotherapy, obtaining a complete remission) and 3 had progressive disease. Median progression- free survival was 7.2 months, and median overall survival was 30 months.Conclusions: Based on this case-series study, the regimen seems to offer a good control of disease (86.9%) and can be considered as an alternative choice for patients who cannot receive continuous infusion.

Tumori 2007; 93(6): 557 - 561

Article Type: ORIGINAL RESEARCH ARTICLE

Authors

Nicla La Verde, Marina Garassino, Claudia Bareggi, Paola Sburlati, Karen Borgonovo, Mariastella Dimaiuta, Cristina Mantica, Silvia Perrone, Valter Torri, Gabriella Farina

Article History

This article is available as full text PDF.

Download any of the following attachments:

Authors

  • La Verde, Nicla [PubMed] [Google Scholar]
    Oncology Department, Azienda Ospedaliera Ospedale Fatebenefratelli e Oftalmico, Milan, Italy
  • Garassino, Marina [PubMed] [Google Scholar]
    Oncology Department, Azienda Ospedaliera Ospedale Fatebenefratelli e Oftalmico, Milan, Italy
  • Bareggi, Claudia [PubMed] [Google Scholar]
    Oncology Department, Azienda Ospedaliera Ospedale Fatebenefratelli e Oftalmico, Milan, Italy
  • Sburlati, Paola [PubMed] [Google Scholar]
    Oncology Department, Azienda Ospedaliera Ospedale Fatebenefratelli e Oftalmico, Milan, Italy
  • Borgonovo, Karen [PubMed] [Google Scholar]
    Oncology Department, Azienda Ospedaliera Ospedale Fatebenefratelli e Oftalmico, Milan, Italy
  • Dimaiuta, Mariastella [PubMed] [Google Scholar]
    Oncology Department, Azienda Ospedaliera Ospedale Fatebenefratelli e Oftalmico, Milan, Italy
  • Mantica, Cristina [PubMed] [Google Scholar]
    Oncology Department, Azienda Ospedaliera Ospedale Fatebenefratelli e Oftalmico, Milan, Italy
  • Perrone, Silvia [PubMed] [Google Scholar]
    Oncology Department, Azienda Ospedaliera Ospedale Fatebenefratelli e Oftalmico, Milan, Italy
  • Torri, Valter [PubMed] [Google Scholar]
    Oncology, Mario Negri Institute, Milan, Italy
  • Farina, Gabriella [PubMed] [Google Scholar]
    Oncology Department, Azienda Ospedaliera Ospedale Fatebenefratelli e Oftalmico, Milan, Italy

Article usage statistics

The blue line displays unique views in the time frame indicated.
The yellow line displays unique downloads.
Views and downloads are counted only once per session.

No supplementary material is available for this article.